公开(公告)号：US20130052670A1

公开(公告)日：2013-02-28

申请号：US13544554

申请日：2012-07-09

申请人： Mary Savage ,  Paul Shughrue ,  Abigail Wolfe ,  Alexander McCampbell

发明人： Mary Savage ,  Paul Shughrue ,  Abigail Wolfe ,  Alexander McCampbell

IPC分类号： G01N33/566 ,  G01N21/64

CPC分类号： G01N33/6896 ,  C07K16/18 ,  C07K2317/24 ,  G01N2800/2821 ,  G01N2800/52

摘要： The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-AP oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and/or target engagement.

摘要翻译： 本发明涉及一种选择性A＆Bgr; 低分子免疫测定能够可靠和敏感地检测A＆bgr; 患者生物样品中的低聚物。 在一个实施方案中，本发明的测定使用一对抗AP寡聚体抗体19.3和82E1来检测和定量A＆bgr; 脑脊液（CSF）样品中的低聚物。 本发明的测定可用于区分来自非AD患者的阿尔茨海默病（AD）患者和/或根据其疾病的严重程度分层AD患者。 本发明的测定法也可以用作可以测量结合的A和Bgr的目标接合测定; 寡聚体作为用于评估治疗功效和/或靶标参与的替代终点。